Sugi Predict

Sugi Predict / Compounds / SCHEMBL2409003

SCHEMBL2409003

SCHEMBL2409003

O=C(Nc1ccc(O)cc1)c1ccc(Cl)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.67
▸ RAB9A P51151 2/20 0.67
▸ SMN1; SMN2 Q16637 1/20 0.67
▸ KMT2A Q03164 4/20 0.66
▸ MAPK1 P28482 2/20 0.66
▸ NT5E P21589 1/20 0.66
▸ SNCA P37840 1/20 0.64
▸ DEGS1 O15121 1/20 0.64
▸ NQO2 P16083 2/20 0.61
▸ PTGS2 P35354 1/20 0.61
▸ KCNQ3 O43525 1/20 0.60
▸ KCNQ2 O43526 1/20 0.60
▸ KCNE1 P15382 1/20 0.60
▸ KCNQ1 P51787 1/20 0.60
▸ NAMPT P43490 1/20 0.59
▸ LMNA P02545 1/20 0.59
▸ MEN1 O00255 3/20 0.58
▸ TDP1 Q9NUW8 1/20 0.58
▸ PRMT1 Q99873 1/20 0.58
▸ ALDH1A1 P00352 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6556039 1.00 NPC1 (0.67) NPC1RAB9ASMN1; SMN2KMT2AMAPK1
SCHEMBL10939703 0.92 NPC1 (0.76) NPC1RAB9ASMN1; SMN2KMT2AMAPK1
SCHEMBL611657 0.92 NPC1 (0.76) NPC1RAB9ASMN1; SMN2KMT2AMAPK1
SCHEMBL9767723 0.92 NPC1 (0.76) NPC1RAB9ASMN1; SMN2KMT2AMAPK1
SCHEMBL8420639 0.90 DEGS1 (0.75) NPC1RAB9ASMN1; SMN2KMT2ASNCA
SCHEMBL899585 0.90 DEGS1 (0.75) NPC1RAB9ASMN1; SMN2KMT2ASNCA
SCHEMBL900928 0.90 DEGS1 (0.75) NPC1RAB9ASMN1; SMN2KMT2ASNCA
SCHEMBL11437835 0.86 HTT (0.58) NPC1RAB9ASMN1; SMN2KMT2AMAPK1
SCHEMBL27918627 0.85 NPC1 (0.67) NPC1RAB9ASMN1; SMN2KMT2AMAPK1
SCHEMBL6710662 0.85 MITF (0.68) NPC1RAB9ASMN1; SMN2KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0409313-A2 Poly carbonates endowed with high-fluidity characteristics and process for preparing them ENICHEM S.p.A. (IT) 1991-01-23 — — EP claimed
JP-3103435-A — — None — — JP disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 — — US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 — — US disclosed
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 — — US disclosed
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 — — US disclosed
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 — — US disclosed
CN-101068797-A Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof MITSUBISHI PHARMA CORP (JP) 2007-11-07 — — CN disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 — — EP disclosed
US-7192982-B2 Modulators of peroxisome proliferator activated receptors LIGAND PHARMACEUTICALS, INC. (US) 2007-03-20 — — US disclosed
US-20050020684-A1 Modulators of peroxisome proliferator activated receptors ELI LILLY AND COMPANY 2005-01-27 — — US disclosed
CN-1543451-A Receptor modulators activated by peroxizonal proliferators (ppar) — 2004-11-03 — — CN disclosed
EP-1392637-A2 MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS ELI LILLY AND COMPANY (US) 2004-03-03 — — EP disclosed
WO-2002100813-A2 MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS ELI LILLY AND COMPANY (US) 2002-12-19 — — WO disclosed
JP-H03103435-A LINEAR THERMOPLASTIC AROMATIC POLYCARBONATE AND ITS PRODUCTION MONTEDIPE SPA 1991-04-30 — — JP disclosed
EP-0409313-A2 Poly carbonates endowed with high-fluidity characteristics and process for preparing them ENICHEM S.p.A. (IT) 1991-01-23 — — EP disclosed
US-4358449-A 1-(1,3-Dioxolan-2-ylmethyl)-1H-1,2,4-triazoles and compositions JANSSEN PHARMACEUTICA, N.V. (BE) 1982-11-09 — — US disclosed
US-4335125-A FUNGICIDES, BACTERICIDES JANSSEN PHARMACEUTICA, N.V. (BE) 1982-06-15 — — US disclosed
US-4223036-A FUNGICIDES, BACTERICIDES JANSSEN PHARMACEUTICA N.V. (BE) 1980-09-16 — — US disclosed
US-4144346-A FUNGICIDES, BACTERICIDES JANSSEN PHARMACEUTICA N.V. (BE) 1979-03-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG NPC1 271/4885RAB9A 2891/4885SMN1; SMN2 4773/4885
US-20050020684-A1 Modulators of peroxisome proliferator activated receptors NCOA4, PPARG, PPARA NPC1 1429/4885RAB9A 3987/4885SMN1; SMN2 4742/4885
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors PPARG, NCOA4, PPARA NPC1 1791/4885RAB9A 3865/4885SMN1; SMN2 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.